Key result
Concomitant tricuspid repair shows no significant association with major postoperative events during redo MVR.
Why the study?
Redo mitral valve replacement is high risk and early mortality alone may underestimate postoperative burden, leaving unclear whether concomitant tricuspid valve repair independently increases major adverse postoperative events.
Does concomitant tricuspid valve repair increase major adverse postoperative events in patients undergoing redo mitral valve replacement?
Observational (n=249)
No
Does concomitant tricuspid valve repair increase major adverse postoperative events in patients undergoing redo mitral valve replacement?
Answers are grounded in this paper and cite their sources.
In patients undergoing redo mitral valve replacement, concomitant tricuspid valve repair is not independently associated with an increased risk of major adverse postoperative events after adjusting for baseline clinical and operative covariates.
Background: Redo mitral valve replacement is a high-risk operation in which early mortality alone may underestimate postoperative burden. We evaluated whether concomitant tricuspid valve repair independently increases major adverse postoperative events after redo mitral valve replacement. Methods: Consecutive patients undergoing redo mitral valve replacement between 2019 and 2025 were retrospectively reviewed. Isolated redo mitral valve replacement was compared with redo mitral valve replacement plus concomitant tricuspid valve repair. The primary endpoint was major adverse postoperative events, defined as early mortality, acute kidney injury, cerebrovascular event, prolonged ventilation, reoperation, deep sternal infection, mechanical circulatory support, or permanent pacemaker implantation. Results: The final cohort included 249 patients: 134 underwent isolated redo mitral valve replacement and 115 underwent concomitant tricuspid valve repair. Patients receiving tricuspid valve repair were older, had higher pulmonary artery pressure, and had a longer interval from the previous operation. They also had longer ventilation, longer intensive care unit stay and higher rates of atrial fibrillation, atrioventricular block, and permanent pacemaker implantation. Early mortality was similar between groups. Major adverse postoperative events occurred in 122 patients. Concomitant tricuspid valve repair was not associated with major adverse postoperative events in univariable analysis. In multivariable analysis, concomitant tricuspid valve repair was not independently associated with MAPE. Increasing age, smoking, lower left ventricular ejection fraction, and longer cardiopulmonary bypass time remained independently associated with MAPE. Conclusions: Early major postoperative morbidity after redo mitral valve replacement was associated primarily with patient-related risk factors and operative complexity. Concomitant tricuspid valve repair was not independently associated with MAPE after adjustment for the available covariates.
No takes yet. Share an insight, caveat, or question.
Timur et al. (2026) conducted an observational in Redo mitral valve replacement (n=249). Concomitant tricuspid valve repair vs. Isolated redo mitral valve replacement was evaluated on Major adverse postoperative events (MAPE) (OR 1.41, 95% CI 0.80-2.53, p=0.20). Concomitant tricuspid valve repair during redo mitral valve replacement was not independently associated with major adverse postoperative events.
Synapse has enriched 10 related papers. Consider them for comparative context: